TORONTO and GLIL YAM, Israel – IM Cannabis Corp. (the “Company” or “IMC”) (CSE:IMCC), one of many world’s pioneering medical hashish corporations with operations in Israel and throughout Europe, introduced as we speak {that a} current peer-reviewed research carried out by Professor Dedi Meiri on the Technion – Israeli Institute of Technology (“Technion”) investigating the associations between phytocannabinoid therapy and migraine frequency, discovered that medical hashish outcomes in long-term discount of migraine frequency in over 60% of handled patients1. The research additionally discovered that medical hashish is related to much less incapacity and decrease antimigraine treatment consumption. Furthermore, Technion’s analysis indicated that two strains used in the research (IMC’s London and Tel-Aviv strains) had been discovered to be particularly efficient.

“At IMC, we have high conviction that the development of evidence-based research in medical cannabis will lead to a new generation of medical products to treat a variety of indications and illnesses over the long-term. We will continue to partner with visionaries and leading researchers such as Professor Dedi Meiri and Technion to advance research and development of medical cannabis as it aligns strongly with our vision of leadership in global medical cannabis,” mentioned Oren Shuster, CEO of IMC. “The results of this study follow our announcement last week of a binding term sheet with MGC Pharmaceuticals Ltd. to distribute CannEpil in Israel for the treatment of refractory epilepsy. As we continue to develop relationships with innovators in research and development, we plan to use our global distribution network to bring a range of high-quality medical cannabis products to patients across the world.”


Professor Dedi Meiri, commented, “In the past five years, my lab, together with the main growers in Israel, have been running the Israeli database project. As part of this project, we have been testing the associations between phytocannabinoid treatment and migraine frequency. In this work we observed that 89% of the respondents reported lower current migraine disability and lower negative impact, and lower rates of opioid and triptan consumption. Moreover, we were able to demonstrate that the respondents consumed cannabis strains with higher doses of the phytocannabinoid ms_373_15c and lower doses of the phytocannabinoid ms_331_18d. Two of the most impactful strains in the study were IMC branded strains, Tel-Aviv and London.”

About IM Cannabis Corp.
IMC is a world medical hashish firm, and a well known Israeli model of medical hashish merchandise. In Europe, IMC has established a medical hashish operation first with its distribution subsidiary in Germany and augmented by strategic agreements with licensed EU-GMP Standard suppliers, making it one of many solely medical hashish corporations with totally built-in operations in Europe. IMC intends to leverage its operational expertise and model to ascertain a foothold in rising medical hashish markets together with Germany, Portugal and Greece. IMC’s core Israeli enterprise contains providing branding, know-how and different mental property-related providers to the Israeli medical hashish market. Its key property in Israel embrace business agreements with licensed producers and an choice to buy licensed entities. IMC has developed proprietary processes in its operations and is energetic in creating and investing in modern know-how for international medical hashish shoppers leveraging its repute and experience in the medical hashish sector.

About Technion
Technion – Israel Institute of Technology, persistently ranked among the many world’s high science and know-how analysis universities, is Israel’s first college. Since its founding in 1912, the institute has educated generations of engineers, architects, and scientists who’ve performed a key position in laying the State of Israel’s infrastructure and establishing its essential high-tech industries. Beginning with 17 college students, Technion has been Israel’s major supply of technological manpower and the nation’s largest complete educational middle for superior science and know-how training, in addition to utilized analysis. In addition, Technion is one among solely a handful of know-how institutes in the world with an affiliated medical faculty.Technion has 18 educational departments in engineering, pure sciences, drugs and structure, in addition to 60 analysis facilities. Students might select from some 50 undergraduate and 82 graduate educational applications. There are at present near 14,000 college students on the Technion (~9,300 BSc, ~2,800 MSc, ~1,000 PhD, and ~ 660 MD). To date, Technion has awarded round 100,000 levels. Technion graduates have introduced the distinctive abilities and penchant for innovation which helped conceive and consolidate the fashionable State of Israel – generally acknowledged to be the “Start-up Nation.”The employees of the Technion contains 620 college members; 1,000 technical and administrative employees; 250 clinicians; and 950 adjuncts and instructors.

Source link